300086 康芝药业
午间休市 06-08 11:30:00
资讯
新帖
简况
康芝药业(300086.SZ)：注射用头孢他啶他唑巴坦钠(3:1)临床试验获批
智通财经 · 05-26
康芝药业(300086.SZ)：注射用头孢他啶他唑巴坦钠(3:1)临床试验获批
康芝药业(300086.SZ)羧甲司坦颗粒获得药品注册证书
智通财经 · 05-19
康芝药业(300086.SZ)羧甲司坦颗粒获得药品注册证书
康芝药业：公司累计收到宏氏投资支付的履约准备金11,300万元
证券之星 · 05-12
康芝药业：公司累计收到宏氏投资支付的履约准备金11,300万元
股市必读：康芝药业（300086）5月8日董秘有最新回复
证券之星 · 05-11
股市必读：康芝药业（300086）5月8日董秘有最新回复
每周股票复盘：康芝药业（300086）Q1净利降21.24%
证券之星 · 05-03
每周股票复盘：康芝药业（300086）Q1净利降21.24%
图解康芝药业年报：第四季度单季净利润同比下降44.01%
证券之星 · 04-29
图解康芝药业年报：第四季度单季净利润同比下降44.01%
康芝药业：公司目前暂无正在开发中的创新药
证券之星 · 04-10
康芝药业：公司目前暂无正在开发中的创新药
BD+业绩双重炸裂，创新药多股涨停，黄金窗口期来了？
格隆汇 · 04-02
BD+业绩双重炸裂，创新药多股涨停，黄金窗口期来了？
股市必读：康芝药业（300086）今年截至3月20日累计跌幅已超30%
证券之星 · 03-23
股市必读：康芝药业（300086）今年截至3月20日累计跌幅已超30%
股市必读：康芝药业（300086）今年截至3月3日累计跌幅已超25%
证券之星 · 03-04
股市必读：康芝药业（300086）今年截至3月3日累计跌幅已超25%
康芝药业最新公告：全资子公司中选国家组织集采药品协议期满品种接续采购
证券之星 · 03-02
康芝药业最新公告：全资子公司中选国家组织集采药品协议期满品种接续采购
康芝药业：1.1亿元作为往来记入其他应付款
证券之星 · 02-10
康芝药业：1.1亿元作为往来记入其他应付款
康芝药业：目前宏氏投资已给公司支付1.1亿元履约准备金
证券日报 · 02-08
康芝药业：目前宏氏投资已给公司支付1.1亿元履约准备金
股市必读：康芝药业（300086）预计2025年全年扣非后净利润亏损1.53亿元至2.16亿元
证券之星 · 02-02
股市必读：康芝药业（300086）预计2025年全年扣非后净利润亏损1.53亿元至2.16亿元
康芝药业：预计2025年全年归属净利润亏损1.68亿元至2.38亿元
证券之星 · 01-30
康芝药业：预计2025年全年归属净利润亏损1.68亿元至2.38亿元
康芝药业盐酸左西替利嗪颗粒中选京津冀赣药品集采
中金财经 · 01-26
康芝药业盐酸左西替利嗪颗粒中选京津冀赣药品集采
康芝药业：截止目前，公司没有与脑机接口类公司合作的项目
证券之星 · 01-23
康芝药业：截止目前，公司没有与脑机接口类公司合作的项目
康芝药业（300086）披露控股股东部分股份质押展期，1月21日股价下跌0.96%
证券之星 · 01-21
康芝药业（300086）披露控股股东部分股份质押展期，1月21日股价下跌0.96%
康芝药业（300086）披露聘任高级管理人员公告，1月15日股价下跌5.04%
证券之星 · 01-15
康芝药业（300086）披露聘任高级管理人员公告，1月15日股价下跌5.04%
康芝药业：大股东已支付1.1亿元履约准备金
证券之星 · 01-12
康芝药业：大股东已支付1.1亿元履约准备金
加载更多
公司概况
公司名称：
康芝药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-05-26
主营业务：
康芝药业股份有限公司的主营业务是儿童用药、母婴健康用品的研发、生产和销售。公司的主要产品是儿童药、成人药、母婴健康用品、医疗器械。
发行价格：
60.00
{"stockData":{"symbol":"300086","market":"SZ","secType":"STK","nameCN":"康芝药业","latestPrice":6.28,"timestamp":1780891548000,"preClose":6.42,"halted":0,"volume":6206200,"delay":0,"changeRate":-0.0218,"floatShares":441000000,"shares":455000000,"eps":-0.5102,"marketStatus":"午间休市","change":-0.14,"latestTime":"06-08 11:30:00","open":6.32,"high":6.5,"low":6.21,"amount":39679100,"amplitude":0.0452,"askPrice":6.29,"askSize":10,"bidPrice":6.28,"bidSize":215,"shortable":0,"etf":0,"ttmEps":-0.5102,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780894800000},"marketStatusCode":3,"adr":0,"adjPreClose":6.42,"symbolType":"stock","openAndCloseTimeList":[[1780882200000,1780889400000],[1780894800000,1780902000000]],"highLimit":7.06,"lowLimit":5.78,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":455124411,"isCdr":false,"pbRate":3.29,"roa":"--","roe":"--","epsLYR":-0.5057,"committee":0.534041,"marketValue":2858000000,"turnoverRate":0.0141,"status":1,"floatMarketCap":2767000000},"requestUrl":"/m/hq/s/300086","defaultTab":"news","newsList":[{"id":"2638597209","title":"康芝药业(300086.SZ)：注射用头孢他啶他唑巴坦钠(3:1)临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2638597209","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638597209?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:11","pubTimestamp":1779786707,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康芝药业 发布公告，近日，公司申报的“注射用头孢他啶他唑巴坦钠(3:1)”获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。本次获得注射用头孢他啶他唑巴坦钠(3:1)增加儿童适用人群及用法用量的临床试验申请的《药物临床试验批准通知书》是公司在药品研发领域的阶段性成果，对公司短期的财务状况、经营业绩不构成重大影响，本次临床试验批准通知书的获得不影响本产品的销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0048","BK0070","300086","BK0239","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636834355","title":"康芝药业(300086.SZ)羧甲司坦颗粒获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2636834355","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636834355?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:15","pubTimestamp":1779182137,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康芝药业(300086.SZ)发布公告，公司近日收到国家药品监督管理局核准签发的羧甲司坦颗粒药品注册证书(证书编号：2026S01525)。公告显示，羧甲司坦颗粒适用于治疗支气管炎、支气管哮喘等疾病引起的痰液粘稠、咳出困难者。公司的羧甲司坦颗粒是以2010年在日本获批上市日本杏林制药株式会社生产的羧甲司坦干糖浆剂(国家药典委员会命名为颗粒剂)为参比制剂，进行研发的。根据米内网数据：2025年国内羧甲司坦全剂型(含颗粒、口服溶液、片剂等)市场销售额约12.1亿元;其中颗粒剂占比约1.38%，对应销售额约1700万元。目前国内羧甲司坦颗粒已批准上市的厂家共有5家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康芝药业(300086.SZ)羧甲司坦颗粒获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0048","BK0070","BK0042","300086","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634842214","title":"康芝药业：公司累计收到宏氏投资支付的履约准备金11,300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634842214","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634842214?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:52","pubTimestamp":1778590374,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业05月12日在投资者关系平台上答复投资者关心的问题。针对控股股东宏氏投资的履约进展，公司已采取相关措施，具体情况如下：1.资金到账情况：公司已与宏氏投资、华夏银行开立三方共管账户。截至目前，公司累计收到宏氏投资支付的履约准备金11,300万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200038160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086","BK0070","BK0048","BK0042","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634259494","title":"股市必读：康芝药业（300086）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634259494","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634259494?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:08","pubTimestamp":1778436494,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，康芝药业报收于7.62元，上涨0.0%，换手率7.23%，成交量31.87万手，成交额2.47亿元。董秘最新回复投资者： 董秘你好，我在股吧看到大家讨论公司年报，关于经营质量与财务规范有一些疑问，因此想请教：① 公司经营现金流大幅改善主要来自控股股东履约款，当前主营业务的真实回款与造血能力是否已有实质改善？烦请说明，谢谢董秘： 尊敬的投资者，您好！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","BK0239","300086","BK0042","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632060876","title":"每周股票复盘：康芝药业（300086）Q1净利降21.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632060876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632060876?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:51","pubTimestamp":1777769469,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，康芝药业报收于7.4元，较上周的7.0元上涨5.71%。本周，康芝药业4月30日盘中最高价报7.49元。股本股东变化股东户数变动截至2026年3月31日，康芝药业股东户数为4.59万户，较2025年12月31日减少1.61万户，减幅26.0%。业绩披露要点财务报告康芝药业2026年一季报显示，一季度主营收入9657.38万元，同比下降14.09%；归母净利润-1174.97万元，同比下降21.24%；扣非净利润-1189.55万元，同比下降11.05%；负债率47.67%，财务费用354.77万元，毛利率60.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300002213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300086","BK0042","BK0070","BK0048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631580366","title":"图解康芝药业年报：第四季度单季净利润同比下降44.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631580366","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631580366?lang=zh_cn&edition=full","pubTime":"2026-04-29 02:46","pubTimestamp":1777401984,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业2025年年报显示，当年度公司主营收入4.66亿元，同比下降0.72%；归母净利润-2.3亿元，同比下降6.82%；扣非净利润-2.03亿元，同比上升4.4%；其中2025年第四季度，公司单季度主营收入1.4亿元，同比上升32.19%；单季度归母净利润-1.34亿元，同比下降44.01%；单季度扣非净利润-1.04亿元，同比下降47.09%；负债率48.56%，投资收益144.86万元，财务费用1788.12万元，毛利率54.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900007289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118371","title":"康芝药业：公司目前暂无正在开发中的创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118371","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626118371?lang=zh_cn&edition=full","pubTime":"2026-04-10 20:52","pubTimestamp":1775825541,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)04月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价从高点回落近50%，公司是否有正在开发中的创新药？康芝药业回复：您好！公司目前暂无正在开发中的创新药。公司在研项目主要聚焦于儿童用药领域，涵盖改良型新药、首仿药以及中药二次开发等方向。敬请广大投资者谨慎决策，注意投资风险。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000039000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","159992","BK1574","BK0048","06978","BK0239","BK0070","BK1161","300086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624157850","title":"BD+业绩双重炸裂，创新药多股涨停，黄金窗口期来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2624157850","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624157850?lang=zh_cn&edition=full","pubTime":"2026-04-02 14:03","pubTimestamp":1775109822,"startTime":"0","endTime":"0","summary":"进入收获期","market":"fut","thumbnail":"https://img3.gelonghui.com/a401d-e32ea773-2592-402d-a56d-8ff49dc1dd78.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-e32ea773-2592-402d-a56d-8ff49dc1dd78.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4283048","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["AAAU","IAUM","600594","518880","GDXD","02186","GLD","DZZ","PHYS","UGL","GCmain","GDXJ","CEF","159992","BK4585","SGCmain","JNUG","SGOL","1OZmain","02162","USG","IAU","OUNZ","IAUI","BK1191","159831","DGP","06978","BTGD","GLDM","DUST","PALL","MGCmain","GDX","GDXY","SGUmain","GDXU","JDST","XME","GLTR","000788","300086","BK0188","GLL","000950","QOmain","600488","NUGT","159934","603222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621743040","title":"股市必读：康芝药业（300086）今年截至3月20日累计跌幅已超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621743040","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621743040?lang=zh_cn&edition=full","pubTime":"2026-03-23 01:44","pubTimestamp":1774201455,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，康芝药业报收于8.21元，下跌2.61%，换手率3.3%，成交量14.54万手，成交额1.21亿元。交易信息汇总股价提醒3月20日康芝药业收盘报8.21元，跌2.61%，当日成交1453.52万元。该股已连续4日下跌，当年累计跌幅30.28%。前10个交易日主力资金累计净流出1.31亿元，同期股价累计下跌9.31%。资金流向3月20日主力资金净流出2087.72万元；游资资金净流出1381.2万元；散户资金净流入3468.93万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300000599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300086","BK0239","BK0042","BK0048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616373203","title":"股市必读：康芝药业（300086）今年截至3月3日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616373203","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616373203?lang=zh_cn&edition=full","pubTime":"2026-03-04 02:43","pubTimestamp":1772563388,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，康芝药业报收于8.81元，下跌1.89%，换手率5.73%，成交量25.26万手，成交额2.28亿元。交易信息汇总股价提醒3月3日康芝药业收盘报8.81元，跌1.89%，当日成交2525.9万元。该股已连续2日下跌，当年累计跌幅25.51%。前10个交易日主力资金累计净流出1.49亿元，期间股价累计下跌7.72%。资金流向3月3日主力资金净流出1214.47万元；游资资金净流入111.43万元；散户资金净流入1103.04万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400001490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0070","300086","BK0239","BK0048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616387046","title":"康芝药业最新公告：全资子公司中选国家组织集采药品协议期满品种接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2616387046","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616387046?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:36","pubTimestamp":1772444178,"startTime":"0","endTime":"0","summary":"康芝药业(300086.SZ)公告称，公司全资子公司河北康芝制药有限公司的布洛芬颗粒产品在国家组织集采药品协议期满品种接续采购中正式中选。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200025959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300086","BK0239","BK0042","BK0048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610640138","title":"康芝药业：1.1亿元作为往来记入其他应付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2610640138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610640138?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:51","pubTimestamp":1770727867,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)02月09日在投资者关系平台上答复投资者关心的问题。投资者提问：宏氏投资已给公司支付1.1亿元履约准备金，有没有加在年度报年度利润里面，还是没加进去亏损这么多，请回答康芝药业回复：尊敬投资者，您好！截至目前，宏氏投资已给公司支付1.1亿元履约准备金，1.1亿元作为往来记入其他应付款。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000036740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0070","BK0048","300086","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609574396","title":"康芝药业：目前宏氏投资已给公司支付1.1亿元履约准备金","url":"https://stock-news.laohu8.com/highlight/detail?id=2609574396","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609574396?lang=zh_cn&edition=full","pubTime":"2026-02-08 22:03","pubTimestamp":1770559380,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月30日，康芝药业在互动平台回答投资者提问时表示，关于大股东回购中山爱护股权事宜，公司始终高度重视，并在积极督促推进。目前，宏氏投资已给公司支付1.1亿元履约准备金，后续公司将继续督促大股东切实履行相关承诺，维护上市公司及全体股东的合法权益，并将严格按监管要求，及时按要求披露相关进展。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-08/doc-inhmcmei7104210.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-08/doc-inhmcmei7104210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","BK0042","BK0048","300086","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608886122","title":"股市必读：康芝药业（300086）预计2025年全年扣非后净利润亏损1.53亿元至2.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608886122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608886122?lang=zh_cn&edition=full","pubTime":"2026-02-02 02:26","pubTimestamp":1769970372,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，康芝药业报收于10.14元，上涨2.22%，换手率10.06%，成交量44.34万手，成交额4.61亿元。康芝药业发布业绩预告，预计2025年全年归属净利润亏损1.68亿元至2.38亿元。公司公告汇总2025年度业绩预告康芝药业发布2025年度业绩预告，预计归属于上市公司股东的净利润亏损16,800.00万元至23,800.00万元，上年同期亏损21,620.85万元。扣除非经常性损益后的净利润预计亏损15,300.00万元至21,600.00万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607001095","title":"康芝药业：预计2025年全年归属净利润亏损1.68亿元至2.38亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607001095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607001095?lang=zh_cn&edition=full","pubTime":"2026-01-30 20:11","pubTimestamp":1769775066,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业发布业绩预告，预计2025年全年归属净利润亏损1.68亿元至2.38亿元。康芝药业2025年三季报显示，前三季度公司主营收入3.26亿元，同比下降10.29%；归母净利润-9661.15万元，同比上升21.28%；扣非净利润-9863.46万元，同比上升30.23%；其中2025年第三季度，公司单季度主营收入9393.36万元，同比下降34.59%；单季度归母净利润-4252.98万元，同比下降94.49%；单季度扣非净利润-4262.75万元，同比下降17.29%；负债率42.86%，财务费用1370.45万元，毛利率53.36%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000041567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606218965","title":"康芝药业盐酸左西替利嗪颗粒中选京津冀赣药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2606218965","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606218965?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:32","pubTimestamp":1769416326,"startTime":"0","endTime":"0","summary":"中访网数据 康芝药业股份有限公司近日发布公告，其产品盐酸左西替利嗪颗粒成功中选由河北省牵头的京津冀赣化学药品集中带量采购。根据公告，该产品中选价格为每盒36.24元。此次集采的首年约定采购量中，河北省为729,299袋，江西省为1,006,393袋。该药品主要用于治疗荨麻疹、过敏性鼻炎、湿疹等病症。 公司表示，此次中标有利于扩大该产品的市场销售规模，提升市场占有率及品牌影响力，预计将对公司的长远发展产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260126/31972498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0042","300086","BK0070","BK0048","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605470141","title":"康芝药业：截止目前，公司没有与脑机接口类公司合作的项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2605470141","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605470141?lang=zh_cn&edition=full","pubTime":"2026-01-23 20:51","pubTimestamp":1769172712,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)01月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司涉及人脑工程吗 或者有意向脑机接口方向发展吗康芝药业回复：您好，感谢您对公司的关注！ 截止目前，公司没有与脑机接口类公司合作的项目。敬请注意投资风险，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300040080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","300086","BK0070","BK0239","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605483852","title":"康芝药业（300086）披露控股股东部分股份质押展期，1月21日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605483852","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605483852?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:21","pubTimestamp":1769005278,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，康芝药业报收于10.34元，较前一交易日下跌0.96%，最新总市值为47.06亿元。该股当日开盘10.34元，最高10.6元，最低10.1元，成交额达2.59亿元，换手率为5.7%。近日，康芝药业发布公告称，公司控股股东海南宏氏投资有限公司将其持有的公司部分股份办理了质押展期，合计质押展期84,900,000股，占其所持股份比例83.83%，占公司总股本比例18.65%。本次质押展期不涉及新增融资，原融资用于补充经营所需资金。展期后质押到期日统一调整至2027年7月15日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100040839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300086","BK0070","BK0048","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603985638","title":"康芝药业（300086）披露聘任高级管理人员公告，1月15日股价下跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603985638","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603985638?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:11","pubTimestamp":1768486275,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，康芝药业报收于10.54元，较前一交易日下跌5.04%，最新总市值为47.97亿元。该股当日开盘11.0元，最高11.0元，最低10.36元，成交额达5.76亿元，换手率为12.33%。公司近日发布公告称，于2026年1月15日召开第七届董事会第二次会议，审议通过《关于聘任王勇先生为公司高级管理人员的议案》，聘任王勇先生为公司副总裁。其持有公司股份30,000股，与主要股东无关联关系，未受过处罚，符合高管任职资格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500040648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0070","300086","BK0239","BK0048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602517198","title":"康芝药业：大股东已支付1.1亿元履约准备金","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517198","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602517198?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:51","pubTimestamp":1768222282,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：大股东什么时候能付清回购中山爱护的回购款？康芝药业回复：尊敬的投资者：您好！感谢您对公司的关注！关于大股东回购中山爱护股权事宜，公司始终高度重视，并在积极督促推进。目前，宏氏投资已给公司支付1.1亿元履约准备金，后续公司将继续督促大股东切实履行相关承诺，维护上市公司及全体股东的合法权益，并将严格按监管要求，及时按要求披露相关进展。敬请谨慎决策，注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200034582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0042","BK0048","300086"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780891562073,"stockEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.1474},{"period":"3month","weight":-0.2945},{"period":"6month","weight":-0.4216},{"period":"1year","weight":0.2136},{"period":"ytd","weight":-0.4663}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0318},{"period":"3month","weight":-0.0234},{"period":"6month","weight":0.032},{"period":"1year","weight":0.1902},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"康芝药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"45927人(较上一季度减少26.00%)","perCapita":"9595股","listingDate":"2010-05-26","address":"海南省海口市秀英区国家高新技术产业开发区药谷工业园药谷三路6号","registeredCapital":"45512万元","survey":" 康芝药业股份有限公司的主营业务是儿童用药、母婴健康用品的研发、生产和销售。公司的主要产品是儿童药、成人药、母婴健康用品、医疗器械。","listedPrice":60},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康芝药业(300086)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康芝药业(300086)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康芝药业,300086,康芝药业股票,康芝药业股票老虎,康芝药业股票老虎国际,康芝药业行情,康芝药业股票行情,康芝药业股价,康芝药业股市,康芝药业股票价格,康芝药业股票交易,康芝药业股票购买,康芝药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康芝药业(300086)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康芝药业(300086)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}